New heart failure drug shows faster benefit than expected, reshaping treatment timelines

A new analysis of sotagliflozin reveals the drug delivers clinical benefits to heart failure patients more quickly than previously documented, potentially accelerating treatment decisions for physicians and insurers. The finding could reshape how rapidly hospitals deploy the medication and affect coverage determinations.

Originaltitel: Time to Benefit With Sotagliflozin in Patients With Worsening Heart Failure